肾移植后免疫抑制用药方案与移植肾长期存活的关系

目的 分析肾移植后不同的免疫抑制用药方案对移植肾长期存活的影响。方法 根据不同用药组合将患者分为环孢素Ａ（ＣｓＡ）、硫唑嘌呤（Ａｚａ）和泼尼松（Ｐｒｅｄ）三联治疗组、ＣｓＡ和Ｐｒｅｄ二联治疗组、Ａｚａ和Ｐｒｅｄ传统二联治疗组。统计分析免疫抑制用药、排斥反应发生及人、肾存活情况；对发生排斥反应的患者追踪其发生排斥前１２个月内的药物更动情况。结果 采用三联治疗的患者人／肾５年存活率（８８％／７８％）显

Relationship between cyclosporine A-based triple therapy and long term survival following renal transplantation

Objective To study the influence of different combinations of CsA, Aza and prednisone on renal graft long-term survival. Methods 497 cases of renal transplant recipients with one-year normal graft function were followed up for 5 years. The patients were divided into 3 groups according to the different combinations of immunosuppressive agents (CsA Aza Pred, CsA Pred or Aza Pred). The transplant recipients' immunosuppressive agents, rejection episodes and survival were analyzed. The drug variation 12 months before graft rejection was retrospectively studied. Results With cyclosporine-based triple therapy, 5-year survival of patient and renal graft was 88*!% and 78*!%, which was significantly higher than traditional double therapy (74*!%/52*!%, P < 0.05 ). The incidence of rejection was significantly reduced ( P < 0.05 ) in the patients receiving cyclosporine-based triple therapy ( P < 0.05 ). The majority of rejection patients used to have a history of drug cessation and reduction. Conclusions Cyclosporine-based triple therapy have a satisfactory long-term result, which is significantly superior to the traditional double therapy.